



FOR IMMEDIATE DISTRIBUTION

Drug Advisory

IMPORTANT

Presence of Bromazolam detected in a recent Moose Jaw Police seizure

SASKATOON - June 6, 2023 - The Prescription Review Program (PRP) has been notified by Health Canada's Drug Analysis Service that a benzodiazepine namely, **Bromazolam** (8-bromo-1-methyl-6-phenyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine), which is under the *Controlled Drug and Substances Act* (Schedule IV, Item 18) was present in **counterfeit alprazolam tablet(s)**.

No co-occurring substances were detected.

The substance was received in the Health Canada Laboratory on April 25, 2023, and is the first detection of this substance of concern, in this form, in the Moose Jaw area.

- The substance may also represent a threat to anyone handling it without taking the appropriate health and safety precautions.
- The Drug Analysis Service has instituted a policy to communicate advisories to clients well as provincial and territorial public health authorities regarding potentially problematic substances. This policy aims to provide information, as part of an early warning system, to warn Canadians of new substances which may pose a potential health hazard.

*The **Prescription Review Program (PRP)** is Saskatchewan's prescription monitoring program. It monitors for potential inappropriate prescribing and inappropriate use of a provincially designated panel of monitored prescription drugs, as listed in [Regulatory Bylaw 18.1](#), which have been deemed subject to misuse or abuse in the province.*

-30-

Information: Prescription Review Program
prp@cps.sk.ca
Telephone: 1-306-244-7355 or 1-800-667-1668